You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,579,321


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,579,321
Title:Pharmaceutical compositions including low dosages of desmopressin
Abstract: The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 .mu.g desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picogram desmopressin per mL plasma/serum. Articles of manufacture and methods of using the above invention are also disclosed.
Inventor(s): Fein; Seymour (New Canaan, CT)
Assignee: Reprise Biopharmaceutics, LLC (New City, NY)
Application Number:12/173,074
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,579,321
Patent Claims: 1. A method for inducing voiding postponement in a patient while reducing the risk that the patient develops hyponatremia comprising delivering to the bloodstream of the patient an amount of desmopressin no more than about 2 ng/kg by intranasal, transdermal, intradermal, transmucosal, or conjunctival administration, said amount being therapeutically effective to produce an antidiuretic effect lasting for no more than between about 4 and about 6 hours.

2. The method of claim 1 comprising delivering to the bloodstream of the patient an amount of desmopressin no more than about 1 ng/kg.

3. The method of claim 1 further comprising advising a patient that fluid intake should be restricted after administration.

4. The method of claim 1 further comprising advising the patient that no water should be taken after administration.

5. The method of claim 1 comprising administering desmopressin to a patient suffering from nocturia, primary nocturnal enuresis (PNE), or incontinence.

6. The method of claim 1 wherein the method produces a plasma/serum desmopressin concentration in the patient of a maximum of no more than about 10 pg/ml.

7. The method of claim 1 wherein the method produces a plasma/serum desmopressin concentration in the patient of a maximum of no more than about 5 pg/ml.

8. A method for inducing voiding postponement comprising administering to a patient an amount of desmopressin sufficient to produce in the patient a urine osmolality ranging above about 300 mOsm/kg for less than about 5 hours after administration.

9. The method of claim 1 or 8 comprising administering the desmopressin by intranasal administration.

10. The method of claim 1 or 8 comprising administering the desmopressin by transdermal administration.

11. The method of claim 1 or 8 comprising administering the desmopressin by intradermal administration.

12. The method of claim 1 or 8 comprising administering the desmopressin by transmucosal administration.

13. The method of claim 1 or 8 comprising administering the desmopressin by conjunctival administration.

14. The method of claim 1 or 8 comprising administering to the patient between 100 and 2000 ng (0.1 .mu.g to 2 .mu.g) desmopressin.

15. The method of claim 8 wherein the method produces a plasma/serum desmopressin concentration in the patient no more than about 10 pg/ml.

16. The method of claim 8 wherein the method produces a plasma/serum desmopressin concentration in the patient no more than about 5 pg/ml.

17. The method of claim 8 comprising delivering to the bloodstream of the patient no more than about 2 ng/kg desmopressin.

18. The method of claim 8 comprising delivering desmopressin to the bloodstream of a patient suffering from nocturia, PNE, or incontinence.

19. A method for inducing voiding postponement in a patient while reducing the risk that the patient develops hyponatremia comprising delivering to the bloodstream of the patient via transdermal, intradermal, transmucosal, or conjunctival administration no more than about 1 ng/kg desmopressin to produce an antidiuretic effect for no more than about four to about six hours.

20. A method for inducing voiding postponement in a patient while reducing the risk that the patient develops hyponatremia comprising delivering to the bloodstream of the patient via intranasal administration no more than about 2 ng/kg of desmopressin so as to produce an antidiuretic effect.

21. The method of claim 20 comprising delivering to the bloodstream of the patient no more than about 1 ng/kg desmopressin.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.